Finance

NewTimeSpace News: Ribo Life Scienceannounced on June 30 that the Company has entered into an equity transfer agreement with shareholder Haihe Asymchem Fund, proposing to acquire a 25.93% equity interest in Xingborun at a consideration of RMB 70 million.

NewTimeSpace · 2026-07-01

NewTimeSpace News: Zhengye International announced on June 30 that Mr. Hu Jianpeng has resigned as Chief Executive Officer due to revised work arrangements. He will remain as Executive Director and President of the Group’s Paper Division after resignation. Mr. Hu Zheng, the Company’s Chairman, was appointed Chief Executive Officer on the same date.

NewTimeSpace · 2026-07-01

NewTimeSpace News: Chiho Environmental Group announced on June 30 that Yu Shang Investment Group (Hong Kong) Limited, its controlling shareholder, transferred 240,772,843 shares of the Company (representing 15% of issued share capital) to Yu Shang Phoenix Capital Management Limited at nil consideration on 15 June 2026.

NewTimeSpace · 2026-07-01

NewTimeSpace News: Anton Oilfield Services announced on June 30 that Tongao Inspection, its indirectly wholly-owned subsidiary, has submitted a listing application to The Stock Exchange of Hong Kong Limited for listing on the Main Board, and the proposed spin-off has obtained written approval from HKEX.

NewTimeSpace · 2026-07-01

NewTimeSpace News: Transcenta Holdings announced on June 30 that pursuant to its share incentive scheme, the Company granted 451,500 award shares to 136 award grantees and 22,500 share options to 9 option grantees.

NewTimeSpace · 2026-07-01

NewTimeSpace News: Yankuang Energy announced on June 30 that its subsidiary Wubo Technology filed a listing application with The Stock Exchange of Hong Kong Limited on the same day for the listing and trading of its shares on the Main Board.

NewTimeSpace · 2026-07-01

NewTimeSpace News: Ares Asia announced on June 30 that Mr. Luo Xiao has resigned as Executive Director due to other work commitments, with the resignation taking effect on June 30, 2026.

NewTimeSpace · 2026-07-01

June 30, 2026, MANSION INTL(08456.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at HKD 44.48 million, decreased by 13.41% YoY

NewTimeSpace · 2026-06-30

GROWN UP GROUP (01842.HK) plans to issue in total 240 million shares by subscription, with estimated net proceeds of HKD 7.8 million.

NewTimeSpace · 2026-06-30

OneRobotics (06600.HK) announced that Mr. Li Zhichen, Chairman and CEO, has voluntarily committed to extending the lock-up period for his directly held 43,648,450 shares to 18 months post-listing, until June 29, 2027. The Company believes this demonstrates Mr. Li's confidence in the Company's future prospects. The 6-month lock-up period for cornerstone investors' 9,484,500 shares expired on June 29, 2026, while the 12-month lock-up for other existing shareholders runs until December 29, 2026.

NewTimeSpace · 2026-06-30

TENCENT(00700.HK) will spend HKD 500.6 million to repurchase 1.17 million shares on Jun 30, 2026 .

NewTimeSpace · 2026-06-30

LI AUTO-W(02015.HK) will spend HKD 199.11 million to repurchase 4.32 million shares on Jun 30, 2026 .

NewTimeSpace · 2026-06-30

By the close of trading on Jun 30, 2026, TH MEDICAL-B(02697.HK) saw a gain of 216.96% in its share price, closing at HKD 400. During the session, it reached an intraday high of HKD 424.8 and touched an intraday low of HKD 326.4.

NewTimeSpace · 2026-06-30

MIDEA GROUP(00300.HK) will spend CNY 296.97 million to repurchase 3.92 million shares on Jun 30, 2026 .

NewTimeSpace · 2026-06-30

June 30, 2026, CDV HOLDINGS(08280.HK) released its Annual Report for the period ended March 31, 2026, Total Revenue stood at CNY 50.46 million, decreased by 62.51% YoY

NewTimeSpace · 2026-06-30

NewTimeSpace News: Shanghai Henlius Biotech Co., Ltd. (02696.HK) announced that HLX48 for injection, an antibody-drug conjugate (ADC) targeting EGFR and c-MET independently developed by the Company, has completed first patient dosing in the Phase I clinical study for the treatment of advanced/metastatic solid tumors in China. As of the date of this announcement, no bispecific antibody-drug conjugates targeting both EGFR and c-MET have been approved for marketing worldwide.

NewTimeSpace · 2026-06-30
Previous1..3637 383940..151     151 pages total